Trial Profile

A multicenter, longitudinal, cohort study assessing the predictors of response or super-response to monoclonal antibodies targeting the Calcitonin Gene- Related Peptide or its receptor in high- frequency episodic or chronic migraine

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Aug 2022 New trial record
28 Jun 2022 Primary endpoint has been met, as per results presented at the 8th Congress of the European Academy of Neurology.
28 Jun 2022 Results assessing the predictors of response (greater than equal to 50%) or super-response (greater than equal to 75%) to monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide (CGRP) in high-frequency episodic (HFEM) or chronic migraine (CM), presented at the 8th Congress of the European Academy of Neurology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com